PANCRAZZI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.926
EU - Europa 3.634
AS - Asia 1.785
SA - Sud America 195
AF - Africa 52
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 2
Totale 10.619
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.889
PL - Polonia 1.372
RU - Federazione Russa 942
SG - Singapore 465
CN - Cina 412
HK - Hong Kong 373
IT - Italia 280
IE - Irlanda 233
SE - Svezia 231
VN - Vietnam 204
BR - Brasile 154
DE - Germania 137
KR - Corea 122
FR - Francia 113
FI - Finlandia 97
UA - Ucraina 68
IN - India 65
GB - Regno Unito 62
CH - Svizzera 45
JO - Giordania 29
AU - Australia 24
CA - Canada 24
JP - Giappone 19
AR - Argentina 15
ID - Indonesia 15
NL - Olanda 15
TR - Turchia 15
IQ - Iraq 12
CI - Costa d'Avorio 10
ES - Italia 10
BD - Bangladesh 9
MA - Marocco 9
EC - Ecuador 8
MX - Messico 8
BG - Bulgaria 7
ZA - Sudafrica 7
PK - Pakistan 6
BE - Belgio 5
DZ - Algeria 5
KE - Kenya 5
NG - Nigeria 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
PH - Filippine 4
TW - Taiwan 4
UZ - Uzbekistan 4
VE - Venezuela 4
AT - Austria 3
CL - Cile 3
EG - Egitto 3
KG - Kirghizistan 3
LT - Lituania 3
MY - Malesia 3
PY - Paraguay 3
SA - Arabia Saudita 3
CZ - Repubblica Ceca 2
IL - Israele 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
TH - Thailandia 2
TN - Tunisia 2
AZ - Azerbaigian 1
BH - Bahrain 1
BJ - Benin 1
CD - Congo 1
CO - Colombia 1
CR - Costa Rica 1
DO - Repubblica Dominicana 1
EU - Europa 1
GE - Georgia 1
GR - Grecia 1
GT - Guatemala 1
GY - Guiana 1
HN - Honduras 1
HU - Ungheria 1
IM - Isola di Man 1
KH - Cambogia 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MK - Macedonia 1
ML - Mali 1
MT - Malta 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
OM - Oman 1
PA - Panama 1
PS - Palestinian Territory 1
RO - Romania 1
SR - Suriname 1
TG - Togo 1
UY - Uruguay 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.619
Salva come PNG Salva come JPEG
Città #
Warsaw 1.371
Santa Clara 975
Ashburn 548
Fairfield 534
Hong Kong 327
Singapore 309
Chandler 279
Woodbridge 232
Dublin 231
Seattle 218
Cambridge 193
Houston 191
Wilmington 165
Beijing 122
Seoul 121
San Jose 120
Jacksonville 111
Ann Arbor 86
Altamura 73
Buffalo 67
Lawrence 67
Los Angeles 65
Princeton 63
Hanoi 56
Ho Chi Minh City 49
Dallas 48
Lauterbourg 48
Boston 46
Bern 44
Mumbai 40
New York 37
Bremen 35
Helsinki 35
Hefei 34
Shanghai 34
Boardman 33
The Dalles 32
Florence 27
Medford 25
Moscow 25
Munich 25
San Diego 24
Melbourne 23
Council Bluffs 19
São Paulo 19
Dearborn 16
Dong Ket 16
Phoenix 16
Orem 15
Paris 15
Tokyo 15
London 14
Redondo Beach 14
Clifton 13
Kent 13
Milan 13
Jakarta 12
Montepulciano 12
Norwalk 11
Turku 11
Abidjan 10
Montreal 10
Frankfurt am Main 9
Falls Church 8
Haiphong 8
Pune 8
Redwood City 8
Salerno 8
Barcelona 7
Brooklyn 7
Da Nang 7
Fuzhou 7
Guayaquil 7
Izmir 7
San Francisco 7
Andover 6
Auburn Hills 6
Hillsboro 6
Manchester 6
Pian di Scò 6
Sofia 6
West Jordan 6
Abuja 5
Cantagallo 5
Chennai 5
Nairobi 5
Newark 5
Newham 5
Tianjin 5
Yubileyny 5
Abu Dhabi 4
Amman 4
Belo Horizonte 4
Brasília 4
Brussels 4
Bắc Ninh 4
Chicago 4
Denver 4
Frankfurt Am Main 4
Guangzhou 4
Totale 7.672
Salva come PNG Salva come JPEG
Nome #
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 380
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 376
GROWTH INHIBITION AND DIFFERENTIATION OF HUMAN BREAST CANCER CELLS BY THE PAFR ANTAGONIST WEB-2086 340
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 335
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 330
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 330
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 321
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 320
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation 311
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 310
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: An observational, hypothesis-generating study 289
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 258
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 240
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 228
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 219
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 219
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 211
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 206
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 205
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 203
A QUANTITATIVE ASSAY FOR JAK2V617F MUTATION IN MYELOPROLIFERATIVE DISORDERS BY ARMS-PCR AND CAPILLARY ELECTROPHORESIS 195
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 194
Mutations and prognosis in primary myelofibrosis. 193
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases 192
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 191
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 189
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. 175
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. 172
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 169
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 159
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 158
A pathobiological pathway linking thrombopoietin, GATA1 and TGFbeta1 in the development of myelofibrosis 157
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 157
CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin. 156
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. 156
Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders–A consensus project of the Italian Society of Hematology 155
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. 154
Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. 152
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. 151
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 151
WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential 149
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. 148
PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. 143
ANALISI MUTAZIONALI DELLE MALATTIE MIELOPROLIFERTAIVE CRONICHE 142
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. 140
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. 137
MPL mutational analysis in chronic myeloproliferative disorders 131
Variegation of the phenotype induced by the GATA-1low mutation in mice of different genetic backgrounds. 126
Analisi mutazionale delle malattie mieloproliferative croniche 121
Primary myelofibrosis with or without mutant MPL: comparison ofsurvival and clinical features involving 603 patients. 102
Internal tandem duplication of FLT3 gene (FLT3/TID) predicts a poor post-remission outcome in adult patients witha cute non-promyelocytic leukemia 100
Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi 96
ANALYSIS OF ASXL1 MUTATIONS IN 215 PATIENTS WITH MYELOFIBROSIS : IMPACT ON DISEASE PHENOTYPE AND PROGNOSIS 94
LNK MUTATIONS IN JAK2 NEGATIVE ERYTHROCYTOSIS 68
Totale 10.704
Salva come PNG Salva come JPEG
Categoria #
all - tutte 28.006
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 28.006
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021103 0 0 0 0 0 0 0 0 0 0 48 55
2021/2022415 22 43 34 16 15 12 17 35 14 9 88 110
2022/20231.170 98 218 67 115 87 193 136 69 105 3 31 48
2023/2024369 13 45 56 17 39 74 11 59 3 14 25 13
2024/20252.748 76 271 196 383 775 432 18 227 139 67 86 78
2025/20262.233 332 307 183 184 287 91 318 105 178 185 63 0
Totale 10.704